$21.95 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (ALNY) This Quarter


Analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will announce sales of $21.95 million for the current quarter, Zacks reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings. The highest sales estimate is $27.70 million and the lowest is $15.44 million. Alnylam Pharmaceuticals reported sales of $21.90 million during the same quarter last year, which would suggest a positive year over year growth rate of 0.2%. The firm is expected to report its next earnings results on Thursday, May 2nd.


On average, analysts expect that Alnylam Pharmaceuticals will report full year sales of $139.42 million for the current fiscal year, with estimates ranging from $91.19 million to $203.96 million. For the next fiscal year, analysts anticipate that the firm will report sales of $363.32 million, with estimates ranging from $253.04 million to $435.23 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Alnylam Pharmaceuticals.

Get Alnylam Pharmaceuticals alerts:

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 7th. The biopharmaceutical company reported ($2.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.27) by $0.18. Alnylam Pharmaceuticals had a negative return on equity of 50.82% and a negative net margin of 1,016.58%. The business had revenue of $21.00 million for the quarter, compared to the consensus estimate of $18.03 million. During the same quarter in the previous year, the company posted ($1.20) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was down 44.6% compared to the same quarter last year.


A number of research analysts have recently weighed in on the company. Cowen reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. Evercore ISI upgraded Alnylam Pharmaceuticals from an “in-line” rating to an “outperform” rating in a report on Wednesday, March 6th. Morgan Stanley upgraded Alnylam Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $122.00 price target on the stock in a report on Tuesday, March 5th. BidaskClub upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $135.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, February 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $133.28.


A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Alnylam Pharmaceuticals by 0.4% during the fourth quarter. FMR LLC now owns 15,154,553 shares of the biopharmaceutical company’s stock valued at $1,104,919,000 after purchasing an additional 54,637 shares during the last quarter. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 7,605,253 shares of the biopharmaceutical company’s stock valued at $665,612,000 after purchasing an additional 66,740 shares during the last quarter. Vanguard Group Inc boosted its position in Alnylam Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc now owns 7,605,253 shares of the biopharmaceutical company’s stock valued at $665,612,000 after purchasing an additional 66,740 shares during the last quarter. BlackRock Inc. boosted its position in Alnylam Pharmaceuticals by 1.0% during the fourth quarter. BlackRock Inc. now owns 6,145,805 shares of the biopharmaceutical company’s stock valued at $448,089,000 after purchasing an additional 61,777 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its position in Alnylam Pharmaceuticals by 6.4% during the fourth quarter. Baillie Gifford & Co. now owns 4,746,850 shares of the biopharmaceutical company’s stock valued at $346,093,000 after purchasing an additional 284,024 shares during the last quarter. 88.62% of the stock is owned by hedge funds and other institutional investors.


Shares of ALNY stock traded up $3.79 on Friday, reaching $91.76. 625,642 shares of the company’s stock traded hands, compared to its average volume of 850,265. Alnylam Pharmaceuticals has a 12-month low of $60.27 and a 12-month high of $153.99. The company has a current ratio of 6.69, a quick ratio of 6.56 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $9.35 billion, a price-to-earnings ratio of -12.12 and a beta of 2.54.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.


Featured Story: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)